BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017By Nasdaq OMXNov 13, 2017, 2:01 PM UTC
BusinessCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical TrialBy Nasdaq OMXNov 13, 2017, 1:31 PM UTC
BusinessGalectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXNov 7, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisBy Nasdaq OMXOct 20, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017By Nasdaq OMXSep 25, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02By Nasdaq OMXSep 12, 2017, 12:30 PM UTC
BusinessPatent for Reducing Inflammatory Response Granted to Galectin TherapeuticsBy Nasdaq OMXJun 21, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02By Nasdaq OMXApr 25, 2017, 12:02 PM UTC
